FOSUN HEALTH Logo

Leukemia Diagnosis

catalogue

Leukemia Diagnosis

Leukemia Diagnosis

Leukemia is unusual in that the first test is one almost everyone has had. A full blood count can suggest the diagnosis within hours, and it is often what prompts everything else. But a count cannot distinguish the types of leukemia from each other, nor from several other conditions — so it opens the question rather than answering it. The answer comes from the marrow, and then from the chromosomes and genes within those cells.

What the blood count shows

A full blood count measures the numbers of red cells, white cells and platelets, and a film report describes what the cells actually look like. Together they are the fastest route to suspecting leukemia, and the pattern matters more than any single number:

  • A raised white cell count, sometimes very high, reflecting the accumulation of abnormal cells rather than a response to infection.
  • A low count of normal white cells, because the abnormal cells have displaced the ones that fight infection — so the total count can be high while the working cells are few.
  • Anaemia and a low platelet count, often the two together, which is what produces the tiredness and bruising.
  • Abnormalities across more than one cell line, which is a pattern that points to the marrow rather than to the blood itself.
  • Blast cells reported on the film — immature cells that should not be circulating, and a finding that leads directly to a marrow examination.

The film and the marrow

The blood film and the marrow examination answer different questions, and both are needed. The film shows what has escaped into the blood; the marrow shows what is happening in the place the disease actually lives.

  • The blood film — a drop of blood spread on a slide and examined under the microscope, describing the size and shape of the cells, whether immature cells are present, and whether there are cells that should not be there at all.
  • The marrow aspirate — a sample of fluid marrow drawn from the back of the hip bone, which gives the individual cells for counting, for flow cytometry and for chromosome and molecular testing. It is the sample that carries the diagnosis.
  • The marrow trephine biopsy — a small core of intact marrow taken at the same time, showing how the cells are arranged and how full the marrow is. Some diseases are only visible in the architecture.
  • The aspirate is often described as "dry" in the most crowded marrows, meaning few cells could be drawn — which is itself a finding rather than a failed test, and the reason the trephine is taken as well.

Flow cytometry: which lineage

Under the microscope, leukemias of different lineages can look similar. Flow cytometry resolves that by measuring the proteins on the surface and inside each cell, and it does so on thousands of cells at once:

  • Myeloid markers — including myeloperoxidase, CD13, CD33 and CD117, identifying acute myeloid leukemia and separating its subtypes.
  • Lymphoid markers — CD19, CD79a and CD10 for B-cell disease, and CD3, CD5 and CD7 for T-cell disease, identifying acute lymphoblastic leukemia and its lineage.
  • Maturity markers — whether the cells express proteins that indicate maturation, which distinguishes acute from chronic disease in cases where the appearance alone is ambiguous.
  • Abnormal patterns — leukemic cells often express combinations of markers that no normal cell does, and recognising that combination is often what confirms the diagnosis.
  • The same panel becomes the monitoring test — the abnormal combination found at diagnosis is what a later, more sensitive test looks for when measuring residual disease.

Chromosomes and genes

The chromosome and gene results are what turn a diagnosis into a treatment plan in leukemia. Three techniques are used, and they answer slightly different questions:

  • Chromosome analysis — examining the cells' chromosomes under the microscope to find gains, losses and rearrangements, which places many patients into a risk group directly.
  • Fluorescence in situ hybridisation — a targeted test for a specific rearrangement, used when a particular fusion gene needs to be confirmed quickly.
  • Polymerase chain reaction and sequencing — detecting fusion genes and mutations at the level of individual genes, and in the case of chronic myeloid leukemia measuring the level of the fusion gene in the blood to follow the response to treatment.
  • Rapid testing for acute promyelocytic leukemia — because that subtype needs treatment started within hours, the fusion gene is confirmed by a fast method rather than waiting for full chromosome analysis.

Risk groups and measurable residual disease

Once the subtype and the molecular results are known, the disease is placed into a risk group, and treatment is chosen accordingly. Two different kinds of measurement are involved, and they are easy to confuse:

  • Risk group at diagnosis — based on age, white cell count, chromosomes and mutations, and used to choose how intensive the treatment should be from the outset.
  • Measurable residual disease — the amount of disease detectable by a sensitive test when the marrow looks normal under the microscope, measured at defined points during treatment.
  • In acute myeloid leukemia, chromosome and gene findings place the disease in a favourable, intermediate or adverse group, which decides whether chemotherapy alone is expected to suffice or a transplant should be planned in first remission.
  • In acute lymphoblastic leukemia, the same findings plus the response in the first weeks of treatment determine intensity, and identify patients for whom a transplant or cell therapy should be considered early.
  • In chronic myeloid leukemia, the level of the fusion gene in the blood at fixed intervals defines whether the drug is working, whether the dose should change, and whether a deep response might eventually allow treatment to stop.
  • In chronic lymphocytic leukemia, Rai or Binet stage, IGHV mutation status and TP53 or del(17p) together decide when treatment begins and whether chemotherapy has any role at all.

Turning the findings into a plan

When the subtype, the molecular results and the risk group are known, treatment can be planned. Several things should be settled before the first dose rather than discovered during it:

  • A written treatment calendar — the regimen, its phases, how many cycles, and the dates at which the marrow will be reassessed.
  • The response criteria stated in advance — what a good and a poor result at each assessment would lead to, including whether a transplant would be considered in first remission.
  • Fertility preservation, discussed and arranged before treatment starts where the patient is of reproductive age, since some regimens affect fertility and the arrangements take time.
  • Prophylaxis and support — anti-infective medication, tumour lysis prevention, transfusion arrangements, and growth factor support where the regimen requires it.
  • A central venous line, planned where treatment involves repeated infusions or drugs that irritate veins.
  • HLA typing for the patient and any siblings if a transplant may be needed, because identifying a donor takes weeks and is best begun early rather than at the moment it is required.
  • Vaccination advice and dental review before treatment, since live vaccines are avoided afterwards and untreated dental infection becomes dangerous when counts are low.

Frequently Asked Questions

How long does it take to confirm a leukemia diagnosis?

The blood count and film are available within hours, and they are usually what prompt the marrow examination. The marrow aspirate can be reported the same day in an urgent situation, particularly when acute promyelocytic leukemia is suspected, because treatment then cannot wait. Flow cytometry and chromosome analysis typically take a few days, and molecular tests a few more, so a complete diagnosis with its risk group usually takes between three and ten days depending on the type. In acute leukemia treatment frequently begins before every result is back, with the plan adjusted as results arrive.

Is the bone marrow test painful?

It is uncomfortable rather than painful, and it is short. Local anaesthetic is used, and most patients describe a brief deep ache or a sharp sensation at the moment the sample is drawn, lasting seconds; with sedation many remember little of it. The whole procedure takes about fifteen minutes. Two samples are usually taken at the same sitting — the fluid aspirate and the small core biopsy — and the site is the back of the hip bone, which is why lying on the front or the side is how it is done. There are no lasting effects, and ordinary activity can be resumed the same day.

Why do I need genetic tests on my marrow?

Because in leukemia the chromosome and gene findings decide the treatment rather than merely describing the disease. In chronic myeloid leukemia the fusion gene is the diagnosis and the target of the drug; in acute promyelocytic leukemia a different fusion gene identifies a subtype treated without conventional chemotherapy; in acute myeloid leukemia the findings place the disease in a risk group that determines whether a transplant is recommended in first remission; and in chronic lymphocytic leukemia the loss of part of chromosome 17 directs treatment away from chemotherapy entirely. These tests are run on the diagnostic marrow, so they cost nothing extra then — but they cannot be redone later once treatment has cleared the marrow.

What is measurable residual disease, and why does it matter?

It is the amount of leukemia still detectable by a sensitive laboratory test when the marrow looks normal under the microscope. A standard marrow examination can only see disease above a certain level, so a result reported as a remission may still conceal a substantial number of leukemic cells. Measurable residual disease testing looks far below that level, and the result at defined points during treatment is one of the strongest indicators of how deeply the treatment has worked — which is why it can change the plan, for example by moving a transplant decision forward or by supporting continuation of the current regimen.

Patient Stories

Stories from our leukemia programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Have the marrow and molecular results reviewed

Upload the marrow aspirate and biopsy reports, the flow cytometry panel, the chromosome and molecular results, the blood film report, and any treatment given so far. Our haematology team will return a written assessment within 48 hours of the file being complete, including whether the subtype is fully classified and what the risk group implies.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*